Indications : התוויות

4.1     Therapeutic indications
Piperacillin/Tazobactam is indicated for the treatment of systemic and/or local infections caused by susceptible organisms.

Piperacillin/Tazobactam in combination with an aminoglycoside is indicated for the treatment of suspected bacterial infections in neutropenic adults and children above 2 years.
Appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

Piperacillin/Tazobactam is indicated for the treatment of the following infections in adults and adolescents:
- Severe pneumonia including hospital-acquired and ventilator-associated pneumonia - Complicated urinary tract infections (including pyelonephritis)
- Complicated intra-abdominal infections
- Complicated skin and soft tissue infections (including diabetic foot infections) Piperacillin/Tazobactam may be used in the management of neutropenic patients with fever suspected to be due to a bacterial infection.
Appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infections and to determine their susceptibilities to Piperacillin/Tazobactam. Because of its broad spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic organisms as listed above, Piperacillin/Tazobactam is particularly useful in the treatment of mixed infections and in presumptive therapy prior to the availability of the results of sensitivity tests.
Therapy with Piperacillin/Tazobactam may, however, be initiated before results of such tests are known. Modification of the treatment may be required once these results become available or if there is no clinical response.
In serious infections presumptive therapy with Piperacillin/Tazobactam may be initiated before susceptibility test results are available.
Piperacillin/Tazobactam acts synergistically with aminoglycosides against certain strains of Pseudomonas aeruginosa. Combined therapy has been successful, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility test become available, antimicrobial therapy should be adjusted.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin/Tazobactam - Fresenius and other antibacterial drugs, Piperacillin/Tazobactam – Fresenius should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.